Full-Time
Updated on 9/3/2026
Neurovascular and peripheral medical devices manufacturer
$18 - $23/hr
Company Historically Provides H1B Sponsorship
Salt Lake City, UT, USA
In Person
On-site in Salt Lake City, Utah; on-site required.
See people who can refer or advise you
Penumbra develops and sells medical devices for neurovascular and peripheral vascular conditions. Its products assist doctors in treating stroke and other vascular diseases by delivering—through systems like the Penumbra System and Indigo System—catheters, coils, and evacuation devices that are placed inside blood vessels. The company differentiates itself with a broad, integrated portfolio and a global sales network across Europe and the Americas, emphasizing engineering and clinical performance. Its goal is to improve patient outcomes and sustain growth by investing in ongoing research and development to expand its capabilities.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Alameda, California
Founded
2004
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Parental Leave
Paid Vacation
Paid Sick Leave
Paid Holidays
Incuvate files patent infringement lawsuit against Penumbra. Complaint alleges Penumbra's THUNDERBOLT(TM) system infringes five Incuvate patents covering blood-clot detection technology. August 25, 2026 15:28 ET | Source: Incuvate LLC IRVINE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) - Incuvate, LLC today announced that it has filed a patent-infringement lawsuit against Penumbra, Inc. in the U.S. District Court for the Northern District of California. The lawsuit, filed August 19, 2026, alleges that Penumbra's recently launched THUNDERBOLT(TM) Neurovascular Thrombectomy System and related components infringe five Incuvate patents directed to real-time aspiration monitoring technology used in catheter-based thrombectomy procedures. Incuvate's patents cover technology that uses pressure sensors, microprocessors, and pre-set pressure thresholds or differentials to provide real-time visual and audible feedback during aspiration procedures. Incuvate alleges that this technology helps distinguish between clot engagement and blood flow and provides clinicians with valuable information during thrombectomy procedures. The complaint identifies Penumbra's THUNDERBOLT system, Penumbra ENGINE vacuum source, THUNDERBOLT tubing and module, and associated RED Reperfusion Catheters as accused products. Incuvate alleges that these products use patented technology to detect flow conditions, including the presence of clot, and provide users with feedback regarding flow status. Through this lawsuit, Incuvate seeks to hold Penumbra accountable for what Incuvate alleges is Penumbra's unauthorized and willful infringement of the technologies embodied in the asserted patents. Incuvate is seeking damages, injunctive relief, and other remedies described in the complaint. A copy of the complaint is available through PACER Monitor in Incuvate, LLC v. Penumbra, Inc., Case No. 4:26-cv-08658. About Incuvate Incuvate works with medical device entrepreneurs to develop early-stage concepts into innovative products and leads them to market via new companies it finances, builds, and manages. Learn more at incuvatellc.com Media Contact Lance Capel Director of Strategy & External Relations [email protected]
Dr. Donald Frei joins Penumbra as Associate Chief Medical Officer of Neuro. August 10, 2026 Penumbra announced today that Donald Frei, MD, FSNIS, FACR, will serve as Associate Chief Medical Officer of Neuro. A nationally recognized neurointerventional surgeon, Dr. Frei brings clinical and research expertise in stroke and neurovascular care to Penumbra's clinical leadership team. Reporting to James Benenati, MD, FSIR, Chief Medical Officer of Penumbra, Dr. Frei will help guide Penumbra's neurovascular clinical strategy, support evidence development, and collaborate with physicians worldwide to advance patient care. "Dr. Frei has dedicated his career to advancing neurovascular care, from pioneering faster stroke recanalization protocols to helping establish the clinical evidence behind therapies that improve patient outcomes," said Dr. Benenati. "His deep clinical expertise, commitment to innovation, and passion for patient care will be invaluable as we continue to expand the impact of our neurovascular technologies around the world." Throughout his career, Dr. Frei has authored more than 200 peer-reviewed publications and contributed to the advancement of neurovascular therapies through extensive clinical research and evidence generation. Recently, Dr. Frei was the co-principal investigator of the THUNDER Study, which demonstrated that Penumbra's CAVT(TM)(Computer Assisted Vacuum Thrombectomy) platform with THUNDERBOLT technology is safe and effective, paving the way for FDA clearance and CE Mark. Dr. Frei was also instrumental in launching the Get Ahead of Stroke(R) campaign to improve stroke triage and expand access to life-saving neuroendovascular care. "With the recent launch of CAVT with THUNDERBOLT, the neurovascular space is prime for transformation," said Dr. Frei. "I look forward to this opportunity to help advance innovation, generate evidence, deepen trust and closer collaboration with our medical and professional societies, and improve access to care so more patients are able to benefit from the latest technology." Dr. Frei is a leading board-certified neurointerventional surgeon and is a past president of the Society of NeuroInterventional Surgery. He earned his medical degree from the University of Cincinnati College of Medicine and completed his residency training in diagnostic radiology at Tulane University Medical Center. He subsequently completed fellowship training in neuroradiology and endovascular surgical neuroradiology at Washington University's Mallinckrodt Institute of Radiology. He has been recognized as a Fellow of the Society of NeuroInterventional Surgery (FSNIS) and a Fellow of the American College of Radiology (FACR).
Penumbra reported second quarter 2026 revenue of $390.0 million, up 14.9% year-over-year. The thrombectomy company's global thrombectomy revenue reached $259.0 million, increasing 12.5%, whilst embolization and access revenue grew 20.0% to $131.1 million. Gross profit margin improved to 67.9%, up 1.9 percentage points from the prior year. Operating income was $41.0 million, with net income of $34.8 million. Total operating expenses stood at $223.9 million, including $6.9 million in acquisition-related costs. Due to Boston Scientific's pending acquisition of Penumbra, the company will not provide full-year 2026 guidance or host a conference call to discuss results. Penumbra operates in over 100 countries, focusing on thrombectomy technologies for conditions including ischaemic stroke and pulmonary embolism.
Penumbra (NYSE:PEN) posts earnings results, misses expectations by $0.27 EPS. July 31, 2026 Key points. * Penumbra reported quarterly EPS of $0.88, missing the $1.15 analyst consensus by $0.27, while revenue of $390.05 million slightly exceeded expectations and rose 14.9% year over year. * Shares were essentially unchanged at about $320, with Penumbra valued at $12.59 billion and trading at a price-to-earnings ratio of 83.58. * Institutional investors and hedge funds own 88.88% of the stock, while analysts maintain a consensus "Hold" rating with an average price target of $360.33. * Interested in Penumbra? Here are five stocks we like better. Penumbra (NYSE:PEN - Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.88 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.15 by ($0.27), FiscalAI reports. The firm had revenue of $390.05 million for the quarter, compared to analysts' expectations of $389.64 million. Penumbra had a net margin of 11.76% and a return on equity of 10.87%. The company's revenue for the quarter was up 14.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.86 EPS. Penumbra stock down 0.0%. Shares of PEN traded down $0.04 during midday trading on Thursday, hitting $320.09. The company had a trading volume of 357,942 shares, compared to its average volume of 376,100. The stock has a market cap of $12.59 billion, a price-to-earnings ratio of 83.58, a PEG ratio of 1.98 and a beta of 0.70. The company's 50 day moving average price is $318.89 and its 200 day moving average price is $330.09. The company has a quick ratio of 3.95, a current ratio of 6.02 and a debt-to-equity ratio of 0.01. Penumbra has a 52 week low of $221.26 and a 52 week high of $362.41. Hedge funds weigh in on Penumbra. A number of hedge funds have recently bought and sold shares of PEN. Guggenheim Capital LLC lifted its holdings in Penumbra by 47.5% during the 4th quarter. Guggenheim Capital LLC now owns 3,506 shares of the company's stock worth $1,090,000 after buying an additional 1,129 shares during the last quarter. Stifel Financial Corp increased its holdings in shares of Penumbra by 16.3% in the 4th quarter. Stifel Financial Corp now owns 3,331 shares of the company's stock valued at $1,036,000 after acquiring an additional 466 shares during the last quarter. Perbak Capital Partners LLP raised its position in shares of Penumbra by 152.2% during the 3rd quarter. Perbak Capital Partners LLP now owns 3,773 shares of the company's stock valued at $956,000 after acquiring an additional 2,277 shares in the last quarter. Aviva PLC acquired a new stake in shares of Penumbra during the 4th quarter valued at approximately $518,000. Finally, Vident Advisory LLC lifted its stake in Penumbra by 15.4% during the fourth quarter. Vident Advisory LLC now owns 1,607 shares of the company's stock worth $500,000 after purchasing an additional 215 shares during the last quarter. 88.88% of the stock is currently owned by institutional investors and hedge funds. Analyst upgrades and downgrades. Several equities research analysts recently issued reports on PEN shares. Wall Street Zen raised shares of Penumbra to a "hold" rating in a research note on Saturday, May 9th. Royal Bank Of Canada restated a "sector perform" rating and set a $374.00 target price on shares of Penumbra in a research note on Thursday, June 11th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Penumbra in a research report on Friday, July 17th. Citigroup cut their price target on Penumbra from $374.00 to $350.00 and set a "neutral" rating on the stock in a research note on Thursday, May 7th. Finally, Evercore restated an "outperform" rating and set a $320.00 price objective on shares of Penumbra in a research note on Monday, July 6th. Three research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Penumbra has a consensus rating of "Hold" and an average target price of $360.33. Discover more Stock Market News About Penumbra. Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra's technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world. At the core of Penumbra's portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Penumbra, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list. While Penumbra currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom.
Magnendo, an MIT spinout developing magnetic robotic navigation technology for neuro-endovascular intervention, has closed an $18 million Series A financing round. The round was led by Penumbra, the thrombectomy company, with participation from new and existing institutional investors. The funding will support productisation of Magnendo's robotic platform and preparation for first-in-human clinical studies. The company's system combines magnetically steerable guidewires with robotic control, medical imaging, and navigation software to help physicians navigate complex vascular anatomy during stroke procedures. Mechanical thrombectomy has transformed acute ischemic stroke treatment, but reaching the treatment site quickly through complex anatomy remains technically demanding. Magnendo's preclinical results suggest the technology could substantially reduce navigation times whilst improving procedural consistency. The company aims to make endovascular procedures faster and more accessible for patients.